- December 11, 2017 | BY
When we introduce a new therapy—whether it’s a re-engineered mosquito, a biologic or a synthetic drug—we have to think about the immediate and long-term implications of the intervention
- December 8, 2017 | BY
Are antibiotics working against themselves, the risk of using hormone-based birth control methods and is the 6-decade-old drug disulfiram making a comeback to cure cancer?
- December 7, 2017 | BY
Bioscience article looks at establishing germ-free models for preclinical research of the microbiota.
- December 6, 2017 | BY
Modulating the microbiome to treat disease, and employing sophisticated tools to ensure that CRISPR edits the right target. Hot topics to look for in 2018.
- December 4, 2017 | BY
What’s percolating in the field of Parkinson’s disease research? Scientists from Charles River and the Michael J. Fox Foundation discuss therapeutic advances, animal models and reproducibility
- December 1, 2017 | BY
Researchers search for clues to the origin of MS, details on how the first artificial DNA cells made a new protein, and is malaria on the rise?
- November 30, 2017 | BY
Our quest to obtain global accreditation inadvertently turns up a glitch in the scientific literature—a bacterium’s fraternal twin. MicroPhyles Case No. 6
- November 28, 2017 | BY
As we move toward correcting diseases in adult-affected tissue, we need better controls and a better understanding of what exactly is being done to our genomes
- November 22, 2017 | BY
The FDA’s actions address the promise of innovative products and mounting concerns over stem cell clinics
- November 21, 2017 | BY
From synthetic biology to super humanized mice, researchers offer glimpses of where cancer research is heading. A report from a Charles River symposium